Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-823778 in type 2 diabetes mellitus
NCT01111955Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2010
- Primary completion
- Jan 2011
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of bms-823778 in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Bristol Myers Squibb. Primary endpoint: Fasting Plasma Glucose at 28 days. Started Jul 2010; status: completed.
02
Drugs
bms-823778
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01111955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01111955.